HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Commercial Speech Regs Constitutionality Debate Opened By Agency

This article was originally published in The Rose Sheet

Executive Summary

FDA invites public comments on the constitutionality of its approach to regulating advertising and marketing practices for cosmetics, drugs and other products in a notice appearing in the May 16 Federal Register

You may also be interested in...



Deputy Chief Counsel Masoudi Will Succeed Troy In Acting Capacity

Gerald Masoudi will be FDA's acting chief counsel after Daniel Troy departs Nov. 24

Deputy Chief Counsel Masoudi Will Succeed Troy In Acting Capacity

Gerald Masoudi will be FDA's acting chief counsel after Daniel Troy departs Nov. 24

FDA First Amendment Application Guidelines Urged By CTFA

FDA should develop guidelines laying out a First Amendment analysis that would be applied prior to any curtailment of marketing "speech" and followed "consistently throughout the agency," the Cosmetic, Toiletry and Fragrance Association asserts in Oct. 28 comments

Related Content

UsernamePublicRestriction

Register

RS010295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel